Published in N Engl J Med on July 31, 2008
Cellulose Sulfate and HIV Transmission Among Women | NCT00153777
Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS (2010) 4.20
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Microbicides & their implications in HIV prevention. Indian J Med Res (2010) 2.36
Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis (2008) 2.25
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials (2009) 2.14
Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One (2008) 2.09
Why primate models matter. Am J Primatol (2014) 2.05
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe (2011) 1.72
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol (2009) 1.52
Vaginal drug delivery systems for HIV prevention. AAPS J (2009) 1.51
Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc (2013) 1.47
Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis. PLoS One (2010) 1.47
Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial. Clin Vaccine Immunol (2011) 1.47
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One (2010) 1.46
Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem (2009) 1.39
Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology (2009) 1.37
State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr (2012) 1.37
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol (2011) 1.30
Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res (2009) 1.30
Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr (2010) 1.27
Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24
Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio (2011) 1.21
Women and HIV in Sub-Saharan Africa. AIDS Res Ther (2013) 1.20
HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS (2009) 1.18
Animal models for microbicide studies. Curr HIV Res (2012) 1.17
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One (2012) 1.16
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res (2010) 1.15
Experiences in conducting multiple community-based HIV prevention trials among women in KwaZulu-Natal, South Africa. AIDS Res Ther (2010) 1.14
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol (2011) 1.13
Twenty-five years of HIV: lessons for low prevalence scenarios. J Acquir Immune Defic Syndr (2009) 1.13
Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One (2010) 1.12
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
Twice-daily application of HIV microbicides alter the vaginal microbiota. MBio (2012) 1.11
HIV incidence among non-pregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa. AIDS Behav (2012) 1.10
Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis (2010) 1.09
Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One (2011) 1.08
Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J Virol (2013) 1.07
The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One (2008) 1.06
Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06
Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a microbicide phase III clinical trial. PLoS One (2010) 1.05
HIV treatment as prevention: the key to an AIDS-free generation. J Food Drug Anal (2013) 1.05
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology (2011) 1.04
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
The Promise of Antiretrovirals for HIV Prevention. Curr Infect Dis Rep (2012) 1.02
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm (2013) 1.02
Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology (2010) 1.02
Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob Agents Chemother (2009) 1.02
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01
Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol (2010) 1.00
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am J Reprod Immunol (2011) 1.00
Advances in the Development of Microbicides for the Prevention of HIV Infection. Curr Infect Dis Rep (2010) 0.99
A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power. HIV Clin Trials (2010) 0.98
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology (2008) 0.97
Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides. Sci Transl Med (2014) 0.97
An evaluation of methods to improve the reporting of adherence in a placebo gel trial in Andhra Pradesh, India. AIDS Behav (2013) 0.97
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. J Acquir Immune Defic Syndr (2016) 0.95
Who will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries? Stat Commun Infect Dis (2010) 0.95
Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities. Curr HIV/AIDS Rep (2013) 0.95
Animal models for microbicide safety and efficacy testing. Curr Opin HIV AIDS (2013) 0.94
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J (2016) 0.94
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. Antimicrob Agents Chemother (2009) 0.93
Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One (2013) 0.93
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial. Obstet Gynecol (2011) 0.91
3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1. Antimicrob Agents Chemother (2010) 0.91
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother (2011) 0.90
Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol (2012) 0.90
Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis. Antimicrob Agents Chemother (2009) 0.90
Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Antiviral Res (2010) 0.90
Microbicides for HIV prevention. Indian J Med Res (2011) 0.90
Microbicides: still a long road to success. Trends Microbiol (2012) 0.90
Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India. Am J Epidemiol (2010) 0.89
Packaging limits and stability of HIV-1 sequences in a coxsackievirus B vector. Vaccine (2009) 0.89
Availability of HIV postexposure prophylaxis services in Los Angeles County. Clin Infect Dis (2009) 0.89
Rethinking the role of the local community in HIV epidemic spread in sub-Saharan Africa: a proximate-determinants approach. HIV Ther (2009) 0.89
Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicide. BMC Microbiol (2013) 0.89
Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol J (2012) 0.88
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis (2012) 0.87
Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation. PLoS One (2014) 0.86
Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection. PLoS One (2013) 0.86
Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis (2011) 0.86
Topical prophylaxis for HIV prevention in women: becoming a reality. Curr HIV/AIDS Rep (2011) 0.86
Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis (2013) 0.86
Non-specific microbicide product development: then and now. Curr HIV Res (2012) 0.85
Contraception and HIV infection in women. Hum Reprod Update (2008) 0.85
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials (2007) 4.93
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Injection drug use, commercial sex work, and the HIV/STI epidemic in the Russian Federation. Sex Transm Dis (2003) 3.20
Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS (2005) 2.92
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Evaluation design for large-scale HIV prevention programmes: the case of Avahan, the India AIDS initiative. AIDS (2008) 2.78
High HIV prevalence and risk behaviors in men who have sex with men in Chennai, India. J Acquir Immune Defic Syndr (2004) 2.66
Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54
Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis (2002) 2.39
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr (2006) 2.30
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
The vaginal microbiota and susceptibility to HIV. AIDS (2014) 2.24
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
When HIV-prevention messages and gender norms clash: the impact of domestic violence on women's HIV risk in slums of Chennai, India. AIDS Behav (2003) 2.12
Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One (2008) 2.09
Intimate partner violence is as important as client violence in increasing street-based female sex workers' vulnerability to HIV in India. Int J Drug Policy (2008) 1.97
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr (2004) 1.97
Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res (2008) 1.95
The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis (2005) 1.95
Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis (2002) 1.88
High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr (2008) 1.81
Monitoring and assessment of wetlands using Earth Observation: the GlobWetland project. J Environ Manage (2008) 1.74
Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr (2002) 1.71
Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS (2006) 1.70
The central role of clients of female sex workers in the dynamics of heterosexual HIV transmission in sub-Saharan Africa. AIDS (2004) 1.69
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav (2011) 1.68
Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr (2008) 1.63
Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction (2011) 1.62
Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr (2005) 1.61
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
Emergency contraception and fertility awareness among university students in Kampala, Uganda. Afr Health Sci (2006) 1.59
A survey of MSM HIV prevention outreach workers in Chennai, India. AIDS Educ Prev (2006) 1.58
Using mathematical modelling to estimate the impact of periodic presumptive treatment on the transmission of sexually transmitted infections and HIV among female sex workers. Sex Transm Infect (2009) 1.53
Association between medical injections and HIV infection in a community-based study in India. AIDS (2005) 1.52
Assessing reported condom use among female sex workers in southern India through examination of condom availability. Sex Transm Infect (2010) 1.50
To what extent is the HIV epidemic in southern India driven by commercial sex? A modelling analysis. AIDS (2010) 1.48
HIV/AIDS stigma: reliability and validity of a new measurement instrument in Chennai, India. AIDS Behav (2007) 1.47
Comparison of HIV-specific CD8 T-cell responses among uninfected individuals exposed to HIV parenterally and mucosally. AIDS (2005) 1.47
Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial. Clin Vaccine Immunol (2011) 1.47
GB virus infection: a silent anti-HIV panacea within? Trans R Soc Trop Med Hyg (2008) 1.44
The emerging HIV epidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav (2010) 1.43
Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS (2012) 1.41
Clinical profile of HIV in India. Indian J Med Res (2005) 1.41
South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med (2007) 1.40
Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme. Sex Transm Infect (2010) 1.38
Condom use within non-commercial partnerships of female sex workers in southern India. BMC Public Health (2011) 1.37
Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire. AIDS (2007) 1.37
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 1.36
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses (2009) 1.35
Acceptability of a microenterprise intervention among female sex workers in Chennai, India. AIDS Behav (2010) 1.34
The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol (2013) 1.33
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses (2005) 1.31
Sexual behaviors of individuals with HIV living in South India: a qualitative study. AIDS Educ Prev (2007) 1.31
Associations between social capital and HIV stigma in Chennai, India: considerations for prevention intervention design. AIDS Educ Prev (2009) 1.31
Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J Int Neuropsychol Soc (2006) 1.30
Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis (2010) 1.29
Dried blood spots (DBS): a valuable tool for HIV surveillance in developing/tropical countries. Int J STD AIDS (2002) 1.29
Domestic violence as risk factor for unwanted pregnancy and induced abortion in Mulago Hospital, Kampala, Uganda. Trop Med Int Health (2006) 1.28
Combined impact of sexual risk behaviors for HIV seroconversion among women in Durban, South Africa: implications for prevention policy and planning. AIDS Behav (2011) 1.28
Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. CMAJ (2007) 1.27
Short-term increase in unsafe sexual behaviour after initiation of HAART in Côte d'Ivoire. AIDS (2008) 1.27
The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS (2003) 1.27
The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS (2012) 1.26
Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India. AIDS (2013) 1.26
High proportion of isosporiasis among HIV-infected patients with diarrhea in southern India. Am J Trop Med Hyg (2007) 1.26
Multilevel and kin selection in a connected world. Nature (2010) 1.26
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS (2008) 1.26
A dose-response relationship between exposure to a large-scale HIV preventive intervention and consistent condom use with different sexual partners of female sex workers in southern India. BMC Public Health (2011) 1.25
HIV epidemic appraisals for assisting in the design of effective prevention programmes: shifting the paradigm back to basics. PLoS One (2012) 1.25
High prevalence of HIV and sexually transmitted infections among male sex workers in Abidjan, Cote d'Ivoire: need for services tailored to their needs. Sex Transm Infect (2012) 1.24
Polling booth surveys: a novel approach for reducing social desirability bias in HIV-related behavioural surveys in resource-poor settings. AIDS Behav (2012) 1.24
The relationship between drug use stigma and HIV injection risk behaviors among injection drug users in Chennai, India. Drug Alcohol Depend (2010) 1.23
Sexual health promotion in Chennai, India: key role of communication among social networks. Health Promot Int (2005) 1.22
Syndromic versus laboratory-based diagnosis of cervical infections among female sex workers in Benin: implications of nonattendance for return visits. Sex Transm Dis (2002) 1.21
Development of an opinion leader-led HIV prevention intervention among alcohol users in Chennai, India. AIDS Educ Prev (2004) 1.20
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr (2013) 1.20
Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J Infect Dis (2007) 1.20
The profile of injection drug users in Chennai, India: identification of risk behaviours and implications for interventions. Subst Use Misuse (2010) 1.18
Domestic violence during pregnancy and risk of low birthweight and maternal complications: a prospective cohort study at Mulago Hospital, Uganda. Trop Med Int Health (2006) 1.18
HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults. J Int Assoc Physicians AIDS Care (Chic) (2012) 1.18
Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDS (2010) 1.17
Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem (2012) 1.16
Novel strategies implemented to ensure high participant retention rates in a community based HIV prevention effectiveness trial in South Africa and Zimbabwe. Contemp Clin Trials (2009) 1.15